Potassium Chloride
KCl — oral extended-release tablets/capsules, oral solution, and injectable concentrate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Treatment of hypokalemia with or without metabolic alkalosis | Adults and children | Electrolyte replacement | FDA Approved |
| Prophylaxis of hypokalemia in patients at risk (e.g., on loop/thiazide diuretics) | Adults and children | Prophylaxis | FDA Approved |
Potassium chloride is the standard potassium salt used to prevent and treat hypokalemia when dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Hypokalemia is defined as serum potassium below 3.5 mEq/L and most commonly arises from diuretic therapy, vomiting, diarrhoea, hyperaldosteronism, or inadequate intake during parenteral nutrition. Potassium depletion sufficient to cause clinical hypokalemia typically requires loss of 200 mEq or more from total body stores. KCl is preferred over other potassium salts (citrate, bicarbonate, gluconate) when the patient has concomitant metabolic alkalosis and/or chloride depletion, which is the most common clinical scenario with diuretic-induced hypokalemia.
Cardiac arrest (in context of hypokalemia-mediated arrhythmia) — Urgent IV potassium replacement is used during cardiac arrest or peri-arrest when hypokalemia is the suspected precipitant. Evidence quality: Expert consensus (AHA/ACLS guidelines)
Hypokalaemic periodic paralysis — Oral or IV potassium for acute episodes; long-term oral supplementation for prophylaxis in familial forms. Evidence quality: Low (case series)
Dosing
Oral Potassium Chloride — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Prophylaxis of hypokalemia (e.g., diuretic co-therapy) | 20 mEq/day | 20 mEq/day | 40 mEq/day (typical prophylactic) | Give with meals and a full glass of water. Divide if >20 mEq/day. Monitor serum K+ periodically |
| Mild–moderate hypokalemia (K+ 3.0–3.4 mEq/L) | 40–80 mEq/day in 2–4 divided doses | Adjust to serum K+ | 40 mEq per single dose; 100 mEq/day | FDA PI: treatment doses range from 40–100 mEq/day. Each dose ≤40 mEq. Recheck K+ every 2–4 hours until stable |
| Severe hypokalemia (K+ <3.0 mEq/L) — if patient can take oral | 40 mEq TID–QID or 20 mEq q2–3h | Titrate to response | 40 mEq per dose; 100 mEq/day | Consider IV if K+ <2.5 mEq/L, ECG changes present, or patient unable to take oral. Concurrent IV may be needed for severe depletion |
Intravenous Potassium Chloride — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate hypokalemia (K+ 2.5–3.5 mEq/L) — peripheral line | 10–20 mEq in 100–250 mL NS | Repeat as guided by serum K+ | 10 mEq/hr; 40 mEq/L concentration; 200 mEq/day | Infuse over 1–2 hours. Preferably in NS (not dextrose — glucose can worsen hypokalemia). Cardiac monitoring recommended if >10 mEq/hr |
| Severe hypokalemia (K+ <2.5 mEq/L or symptomatic) — central line | 20–40 mEq in 100 mL NS | Titrate based on hourly K+ checks | 40 mEq/hr (central line only); 400 mEq/day | REQUIRES continuous ECG monitoring and hourly serum K+. Central line mandatory for rates >10 mEq/hr. NEVER give undiluted IV push — risk of fatal cardiac arrest |
| Maintenance IV supplementation (e.g., NPO patients) | 20–40 mEq/L in maintenance IV fluids | 1–2 mEq/kg/day (adults) | 40 mEq/L in peripheral fluids | Add to NS or LR bag; mix by inversion ≥5 times. Include all K+ sources in calculations. Typical daily requirement: 40–80 mEq/day |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Oral replacement — children | 1–2 mEq/kg/day in 2–4 divided doses | Adjust to serum K+ | 3 mEq/kg/day; single dose ≤40 mEq | Use liquid formulation in younger children. Give with food. Safety and effectiveness established via published literature (FDA PI) |
| IV replacement — children (K+ ≥2.5 mEq/L) | 0.5 mEq/kg in diluted NS | Repeat per serum K+ | 0.5 mEq/kg/hr; max 10 mEq/hr without cardiac monitoring | Rates >0.5 mEq/kg/hr or >10 mEq/hr require PICU-level cardiac monitoring. Max 40 mEq per intermittent dose in PICU |
Concentrated potassium chloride (2 mEq/mL) must ALWAYS be diluted before IV administration. Undiluted IV push of KCl causes immediate fatal cardiac arrest. Concentrated KCl ampoules should be stored separately from other medications in clinical areas and should ideally be restricted to pharmacy-prepared, ready-to-administer solutions. Many institutions have removed concentrated KCl from ward stock as a patient safety measure (ISMP High-Alert Medication).
Hypokalemia is often refractory to potassium replacement if concurrent hypomagnesaemia is not corrected. Magnesium depletion impairs the renal tubular ability to retain potassium. Check serum magnesium in any patient with persistent or refractory hypokalemia and replace if Mg <2.0 mg/dL (typically magnesium sulfate 2–4 g IV or magnesium oxide 400–800 mg orally).
Pharmacology
Mechanism of Action
Potassium is the principal intracellular cation of most body tissues, with intracellular concentrations of approximately 150–160 mEq/L maintained against a plasma concentration of 3.5–5.0 mEq/L by the Na+/K+-ATPase pump. This steep concentration gradient is essential for maintaining resting membrane potential, which governs the excitability of nerve and muscle cells. Potassium participates in nerve impulse transmission, cardiac and skeletal muscle contraction, acid-base regulation, and maintenance of normal renal function. Potassium chloride supplementation directly replenishes depleted potassium stores; the chloride ion simultaneously corrects the metabolic alkalosis that frequently accompanies diuretic-induced potassium depletion. The usual dietary intake of potassium is 50–100 mEq per day, and under steady-state conditions, the amount absorbed from the gastrointestinal tract equals the amount excreted by the kidneys.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral: rapidly absorbed from GI tract (solution > ER forms in rate, but 24-h bioavailability equivalent); IV: 100% by definition | ER formulations reduce peak GI mucosal concentration, lowering risk of local ulceration compared to liquid or immediate-release |
| Distribution | 98% intracellular (150–160 mEq/L); 2% extracellular (3.5–5.0 mEq/L); active transport via Na+/K+-ATPase | Serum K+ does not reliably reflect total body stores — a 1 mEq/L drop in serum K+ may represent a deficit of 200–400 mEq |
| Metabolism | No metabolism — K+ enters the normal body potassium pool as a physiological ion | No CYP involvement; no hepatic drug interactions. Acid-base status directly affects transcellular K+ shifts |
| Elimination | ~90% renal; ~10% faecal; small amount in sweat. Renal excretion regulated by aldosterone, distal tubular flow, and acid-base status | Impaired renal function is the single greatest risk factor for hyperkalemia from supplementation. Dose reduction essential in CKD. |
Side Effects
Adverse reactions to potassium chloride are primarily gastrointestinal (with oral formulations) and cardiovascular (with IV administration or hyperkalemia from any route). Because potassium chloride has been used for decades and adverse reactions are reported voluntarily, precise incidence rates are not available from controlled trials. The data below reflect FDA-labelled adverse reactions and clinical experience.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | Common (FDA PI: most common AE) | Dose-related GI irritation; take with meals and a full glass of water to mitigate |
| Vomiting | Common | More frequent with liquid preparations and immediate-release forms than ER tablets |
| Abdominal pain / discomfort | Common | Due to local osmotic and irritant effects on GI mucosa; empty-stomach administration worsens risk |
| Diarrhoea | Common | Osmotic effect in the GI tract; generally self-limiting with continued use |
| Flatulence | Common | Typically mild; may improve with ER formulations |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Skin rash | Rare (FDA PI) | Reported rarely; discontinue if allergic-type reaction suspected |
| IV site pain / phlebitis | Common with peripheral IV | Concentrations >40 mEq/L via peripheral line increase risk of venous irritation. Use largest available peripheral vein. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hyperkalemia | Dose- and renal function-dependent | Hours to days after excessive dosing or in renal impairment | Stop KCl immediately. ECG, IV calcium gluconate for cardiac stabilisation, insulin + dextrose, sodium bicarbonate, kayexalate or patiromer for K+ removal. Emergent dialysis if refractory. |
| Cardiac arrhythmias / arrest (from hyperkalemia or rapid IV administration) | Potentially fatal | Immediate (IV push) or hours (excess supplementation) | Undiluted IV push is FATAL. Even diluted IV must follow rate/concentration limits. Continuous ECG for rates >10 mEq/hr. |
| GI ulceration, stenosis, obstruction, or perforation | Uncommon (FDA PI; reported with solid oral forms) | Days to weeks with prolonged mucosal contact | Discontinue immediately. Evaluate for obstruction/perforation. Consider liquid formulation in patients with dysphagia or motility disorders. |
| GI bleeding | Uncommon (FDA PI) | Variable | Discontinue KCl. Investigate source of bleeding. Switch to liquid formulation if supplementation must continue. |
Hyperkalemia is the most dangerous adverse effect of potassium chloride and can be fatal. It is usually asymptomatic until severe, manifesting only as an elevated serum potassium concentration or ECG changes (peaked T waves, widened QRS, loss of P waves, sine wave pattern, and ultimately ventricular fibrillation or asystole). Risk factors include renal impairment, concurrent RAAS inhibitors or potassium-sparing diuretics, acidosis, extensive tissue breakdown, and adrenal insufficiency. Always check renal function and baseline serum potassium before initiating supplementation, and monitor periodically during therapy.
Drug Interactions
Potassium chloride is not hepatically metabolised and has no CYP-mediated interactions. The clinically critical interactions are pharmacodynamic — any drug or condition that impairs potassium excretion or promotes potassium retention increases the risk of life-threatening hyperkalemia when combined with potassium supplementation.
Monitoring
-
Serum Potassium
Baseline, then periodically during maintenance; q2–4h during IV repletion
Routine Target range: 3.5–5.0 mEq/L (4.0–5.0 mEq/L if on digoxin). Ensure proper venipuncture technique — tourniquet-related haemolysis or fist clenching can artefactually elevate K+ readings. In IV repletion for severe hypokalemia, recheck every 1–2 hours. -
ECG / Cardiac Monitor
Continuous during IV infusion >10 mEq/hr
Routine Hypokalemia ECG signs: flattened/inverted T waves, prominent U waves, ST depression, prolonged QT. Hyperkalemia ECG progression: peaked T waves → widened QRS → loss of P wave → sine wave → VF/asystole. Any ECG changes warrant immediate action. -
Serum Magnesium
Baseline; if K+ refractory to replacement
Trigger-based Concurrent hypomagnesaemia renders hypokalemia refractory to potassium repletion. Replace magnesium first or simultaneously if Mg <2.0 mg/dL. -
Renal Function (Cr, eGFR)
Baseline; periodically in chronic users
Routine Impaired renal function is the single greatest risk factor for iatrogenic hyperkalemia. Start at the low end of dosing range in CKD. Avoid or use with extreme caution if eGFR <30 mL/min. -
Acid-Base Status
In complex hypokalemia or critical illness
Trigger-based Alkalosis drives K+ intracellularly (lowers serum K+); acidosis drives K+ extracellularly (raises serum K+). Correct acid-base disturbances alongside potassium replacement for accurate interpretation of serum levels. -
IV Site Inspection
Continuously during IV infusion
Routine Monitor for pain, swelling, or phlebitis at the infusion site. Extravasation of concentrated KCl causes tissue necrosis. Stop infusion immediately if extravasation suspected.
Contraindications & Cautions
Absolute Contraindications
- Hyperkalemia (serum K+ ≥5.5 mEq/L) — supplementation will worsen and can cause fatal arrhythmias
- Concurrent use with triamterene or amiloride — risk of severe hyperkalemia (FDA PI: contraindicated)
- Renal failure with oliguria/anuria — inability to excrete potassium makes any supplementation dangerous
- Untreated Addison’s disease — adrenal insufficiency impairs potassium excretion via aldosterone deficiency
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment (eGFR <30 mL/min) — Use only if documented hypokalemia, with frequent K+ monitoring and low initial doses. Nephrology guidance recommended.
- Concurrent RAAS inhibitors (ACE inhibitors, ARBs, spironolactone, eplerenone, aliskiren) — Potassium supplementation requires careful justification and close monitoring when these agents are in use.
- Structural GI abnormalities (strictures, oesophageal compression from enlarged left atrium, GI obstruction) — Solid oral KCl may become arrested, causing ulceration or perforation. Use liquid formulation.
Use with Caution
- Elderly patients — Higher likelihood of decreased renal function; start at low end of dosing range (FDA PI)
- Cirrhosis — Initiate at the low end of the dosing range (FDA PI)
- Metabolic acidosis — Acidosis shifts K+ extracellularly; serum K+ may appear normal despite total body depletion. Once acidosis is corrected, K+ will fall. Anticipate the need for replacement but interpret serum levels in context of pH.
- Extensive tissue breakdown (burns, crush injuries, rhabdomyolysis, tumour lysis) — Massive release of intracellular K+ can cause hyperkalemia even without supplementation.
The Institute for Safe Medication Practices (ISMP) classifies concentrated potassium chloride injection as a High-Alert Medication. Fatal hyperkalemia from accidental undiluted IV administration has been widely documented. Best practice: remove concentrated KCl from ward stock; use only pharmacy-prepared, ready-to-administer solutions; require independent double-checks before administration; use smart infusion pumps with dose-error reduction software.
Patient Counselling
Purpose of Therapy
Potassium chloride replaces potassium that the body has lost or cannot get enough of from food alone. Low potassium can cause muscle weakness, cramps, irregular heartbeat, and fatigue. This medication is often prescribed alongside water tablets (diuretics) that cause the body to lose potassium in the urine. Taking potassium as directed helps keep the heart and muscles working properly.
How to Take
Take oral potassium with meals and a full glass of water or other liquid to reduce stomach upset. Swallow extended-release tablets whole — do not crush, chew, or suck them. Extended-release capsules may be opened and the contents sprinkled onto soft food (applesauce or pudding) and swallowed immediately without chewing. If using a liquid preparation, dilute in at least 4 ounces (120 mL) of cold water before drinking. Take the medicine as prescribed — do not take extra doses even if you think your potassium is low.
Sources
- Potassium Chloride Extended-Release Tablets, USP — Full Prescribing Information. Multiple manufacturers. Initial U.S. Approval: 1948. DailyMed Representative FDA-approved label for oral KCl ER tablets; provides dosing, contraindications, adverse reactions, and drug interaction data used throughout this monograph.
- Potassium Chloride Extended-Release Capsules — Full Prescribing Information. Granules Pharmaceuticals Inc. DailyMed FDA PI for ER capsule formulation including pediatric use statement and RAAS inhibitor interaction warnings.
- K-TAB (potassium chloride extended-release tablets, USP) — Prescribing Information. AbbVie Inc. FDA Label Brand-name reference label providing additional dosing and GI safety data for wax-matrix potassium formulations.
- Gennari FJ. Hypokalemia. N Engl J Med. 1998;339(7):451–458. doi:10.1056/NEJM199808133390707 Landmark review of hypokalemia pathophysiology, clinical manifestations, and management principles; establishes the 200–400 mEq deficit per 1 mEq/L serum K+ drop framework.
- Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant. 2007;22(12):3471–3477. doi:10.1093/ndt/gfm471 Demonstrates the risk of overcorrection to hyperkalemia during inpatient potassium repletion, supporting conservative dosing and frequent monitoring.
- Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice. Arch Intern Med. 2000;160(16):2429–2436. doi:10.1001/archinte.160.16.2429 Expert consensus on potassium replacement thresholds and targets, including guidance for patients on digoxin (maintain K+ ≥4.0 mEq/L).
- Panchal AR, Bartos JA, Cabanas JG, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16 Suppl 2):S366–S468. doi:10.1161/CIR.0000000000000916 AHA/ACLS guidelines addressing electrolyte management in cardiac arrest, including recommendations for emergent potassium correction.
- Institute for Safe Medication Practices (ISMP). ISMP List of High-Alert Medications in Acute Care Settings. ismp.org Classifies concentrated potassium chloride for injection as a high-alert medication requiring special safeguards to prevent fatal administration errors.
- Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10(6):1050–1060. doi:10.2215/CJN.08580813 Comprehensive review of renal and extrarenal potassium handling, aldosterone-mediated regulation, and the effects of acid-base disturbances on potassium distribution.
- Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649–2652. doi:10.1681/ASN.2007070792 Elucidates the mechanism by which magnesium depletion impairs renal potassium conservation via ROMK channel effects, explaining refractory hypokalemia.
- Potassium. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. Updated 2024 Oct 5. NCBI Bookshelf Comprehensive pharmacology review covering oral and IV dosing guidelines, PK properties, adverse effects, and special population dosing for potassium salts.
- Sterns RH, Cox M, Feig PU, Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore). 1981;60(5):339–354. doi:10.1097/00005792-198109000-00002 Classic review of internal potassium balance including insulin, catecholamine, and acid-base effects on transcellular K+ shifts relevant to clinical interpretation.